We are live on
!
Find out more
SCM
Soleus Capital Management Portfolio holdings
AUM
$2.47B
1-Year Est. Return
115.63%
This Fund
S&P 500
This Quarter
Est. Return
+34.6%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$555M
AUM Growth
-$203M
(-27%)
Cap. Flow
-$287M
Cap. Flow
% of AUM
-51.67%
Top 10 Holdings %
Top 10 Hldgs %
64.54%
Holding
90
New
25
Increased
22
Reduced
13
Closed
18
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
THER
THERATECHNOLOGIES INC COM
THER
|
+$26.9M |
| 2 |
Krystal Biotech
KRYS
|
+$11.4M |
| 3 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$10.8M |
| 4 |
AstraZeneca
AZN
|
+$9.76M |
| 5 |
C4 Therapeutics
CCCC
|
+$7.78M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVTA
Invitae Corporation
NVTA
|
+$10.2M |
| 2 |
Vericel Corp
VCEL
|
+$7.3M |
| 3 |
EPIX
ESSA Pharma
EPIX
|
+$7.1M |
| 4 |
MRSN
Mersana Therapeutics
MRSN
|
+$5.5M |
| 5 |
DarioHealth
DRIO
|
+$5.02M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 90.73% |
| 2 | Consumer Staples | 1.79% |
| 3 | Real Estate | 0.62% |
| 4 | Financials | 0.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ALXN
26
DELISTED
Alexion Pharmaceuticals
ALXN
| $3.87M | 0.7% |
25,318
+6,380
| +34% | +$987K |
|
27
Establishment Labs
ESTA
$2.69B
| $3.82M | 0.69% |
61,151
-5,770
| -9% | -$333K |
|
28
4D Molecular Therapeutics
FDMT
$537M
| $3.73M | 0.67% |
+86,100
| New | +$3.81M |
|
|
CUTR
29
DELISTED
Cutera, Inc.
CUTR
| $3.61M | 0.65% |
+120,000
| New | +$3.55M |
|
30
Philips
PHG
$26B
| $3.48M | 0.63% |
+75,279
| New | +$3.42M |
|
|
31
DarioHealth
DRIO
$74.7M
| $3.44M | 0.62% |
8,941
-11,139
| -55% | -$5.02M |
|
32
Rafael Holdings
RFL
$106M
| $3.42M | 0.62% |
86,836
-19,367
| -18% | -$628K |
|
|
KNTE
33
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $3.4M | 0.61% |
+109,000
| New | +$3.8M |
|
34
NovoCure
NVCR
$1.87B
| $3.35M | 0.6% |
25,325
+326
| +1% | +$51.6K |
|
|
ALPN
35
DELISTED
Alpine Immune Sciences Inc
ALPN
| $3.32M | 0.6% |
313,064
+272,000
| +662% | +$3.39M |
|
36
Edgewise Therapeutics
EWTX
$4.84B
| $3.25M | 0.59% |
+100,000
| New | +$3.24M |
|
|
ARYD
37
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
| $3.14M | 0.57% |
+300,000
| New | +$3.24M |
|
|
TCRR
38
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $3.14M | 0.57% |
142,137
-57,730
| -29% | -$1.57M |
|
|
SIEN
39
DELISTED
Sientra, Inc.
SIEN
| $2.75M | 0.5% |
+37,790
| New | +$2.41M |
|
40
Dyne Therapeutics
DYN
$4.89B
| $2.71M | 0.49% |
+174,360
| New | +$3.37M |
|
41
Revolution Medicines
RVMD
$41.9B
| $2.62M | 0.47% |
+57,200
| New | +$2.57M |
|
42
DexCom
DXCM
$31.2B
| $2.49M | 0.45% |
27,740
-4,920
| -15% | -$462K |
|
|
RNAM
43
DELISTED
Avidity Biosciences
RNAM
| $2.38M | 0.43% |
+109,130
| New | +$2.67M |
|
44
Merck
MRK
$317B
| $2.32M | 0.42% |
31,551
+1,782
| +6% | +$131K |
|
|
NARI
45
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $2.29M | 0.41% |
+21,450
| New | +$2.23M |
|
|
ATXS
46
DELISTED
Astria Therapeutics
ATXS
| $2.24M | 0.4% |
+129,167
| New | +$2.33M |
|
47
NeoGenomics
NEO
$2.02B
| $2.22M | 0.4% |
45,951
| – | – |
|
|
FOCL
48
EDAP TMS S.A.
FOCL
$228M
| $2.1M | 0.38% |
+249,566
| New | +$2.03M |
|
|
RNLX
49
DELISTED
Renalytix plc American Depositary Shares
RNLX
| $2.05M | 0.37% |
+80,000
| New | +$2M |
|
|
EIGR
50
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $1.89M | 0.34% |
7,117
+926
| +15% | +$292K |
|
Similar funds
TW
M
SG
BL
FFA
GWM
Q
SIM
Soleus Capital Management's Q1 2021 Portfolio in Review
As of Q1 2021, Soleus Capital Management held 90 positions worth $555M, down 27% from $758M the previous quarter. Its ten largest holdings account for 65% of the portfolio.
Soleus Capital Management withdrew a net $287M in Q1 2021, closing 18 positions and reducing 13 holdings. Its most notable exit was Invitae Corporation, an estimated $10.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 44% a quarter earlier, followed by Consumer Staples and Real Estate.
Against the trend, Soleus Capital Management opened a new position in THERATECHNOLOGIES INC COM worth $26.9M.
- Soleus Capital Management's largest Q1 2021 buy was THERATECHNOLOGIES INC COM: 6,951,347 shares worth $26.9M.
- Soleus Capital Management added most to Krystal Biotech in Q1 2021, an estimated $11.4M increase.
- Soleus Capital Management's biggest Q1 2021 reduction was ESSA Pharma, cutting an estimated $7.1M.
- Soleus Capital Management fully exited Invitae Corporation in Q1 2021, selling an estimated $10.2M.
- Soleus Capital Management's ten largest holdings make up 65% of its $555M portfolio in Q1 2021.
- Soleus Capital Management opened 25 new positions and closed 18 in Q1 2021.
- Soleus Capital Management's portfolio value fell 27% quarter-over-quarter to $555M.
Based on Soleus Capital Management's 13F filing for Q1 2021, filed 17 May 2021.